|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
o AmpliMed Corp., of Tucson, Ariz., raised $9.25 million after completing its Series A preferred stock offering. Last September, the company said it raised $5 million to open the round. Valley Ventures III LP led the financing, with added investments from Biotech Insight Management, InvestBio, Solstice Capital and Village Ventures. AmpliMed, which is developing cancer chemotherapies, said the funding would allow it to continue clinical development of its lead drug, Amplimexon (imexon), through Phase II studies in malignant melanoma and pancreatic adenocarcinoma.
o Anadys Pharmaceuticals Inc., of San Diego, and LG Life Sciences Ltd., of Seoul, South Korea, ...